Cogent Biosciences

Company snapshot

The pharmaceutical and biotech industries experienced a tremendous amount of change this past decade. For companies to remain relevant and competitive, they must respond quickly and effectively to the unique challenges they face. Our company was started to assist companies in navigating these hurdles. Cogent has earned a reputation for reliability regarding our partnership to our clients. We belie

• 13 active pipeline program(s) linked via ClinicalTrials.gov.
• 10 US patent(s) indexed to this assignee profile.
• 13 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Cogent Biosciences. Not investment advice.

• Peer + 0 momentum

  Alaunos Therapeutics

  TA overlap score 26.8

Recent activity

Latest pipeline, patent, and corporate events for Cogent Biosciences.

1. Jun 8, 2026 Clinical update

   CGT9486 plus sunitinib — Phase 3

2. Jun 8, 2026 Clinical update

   Bezuclastinib in combination with sunitinib — Phase 2

3. Jun 8, 2026 Clinical update

   ACTR T Cell Product — Phase 1

4. Jun 5, 2026 Clinical update

   CGT9486 — Phase 2

5. Jun 5, 2026 Clinical update

   Bezuclastinib Tablets (Formulation A) — Phase 2

View all clinical trial activity →

• What is Cogent Biosciences?

  Cogent Biosciences is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker COGT. Primary therapeutic focus areas include Lymphoma, Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis, Solid Tumor, Multiple Myeloma. NovaPharmaNews links 1

• Is Cogent Biosciences publicly traded?

  Yes. Cogent Biosciences is listed with ticker COGT on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Cogent Biosciences develop or market?

  We link 8 drug profile(s) where Cogent Biosciences is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/cogent-biosciences#company-drugs.

• What are the latest developments for Cogent Biosciences?

  In the last 12 months our linked public records show 13 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Cogent Biosciences focus on?

  Cogent Biosciences focuses on Lymphoma, Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis based on our analysis of their pipeline programs and drug development activities.